

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## ADRA2A RABBIT PAB

Cat.#: S221780

Product Name: Anti-ADRA2A Rabbit Polyclonal Antibody

Synonyms: ADRA2; ADRAR; ZNF32; ADRA2R; ALPHA2AAR

**UNIPROT ID:** P08913 (Gene Accession - NP\_000672)

**Background:** Alpha-2-adrenergic receptors are members of the G protein-coupled receptor superfamily. They include 3 highly homologous subtypes: alpha2A, alpha2B, and alpha2C. These receptors have a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system. Studies in mouse revealed that both the alpha2A and alpha2C subtypes were required for normal presynaptic control of transmitter release from sympathetic nerves in the heart and from central noradrenergic neurons; the alpha2A subtype inhibited transmitter release at high stimulation frequencies, whereas the alpha2C subtype modulated neurotransmission at lower levels of nerve activity. This gene encodes alpha2A subtype and it contains no introns in either its coding or untranslated sequences.

Immunogen: Synthetic peptide of human ADRA2A

Applications: ELISA, IHC

Recommended Dilutions: IHC: 25-100; ELISA: 5000-10000

Host Species: Rabbit

**Clonality:** Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG

Purification: Antigen affinity purification

Species Reactivity: Human, Mouse, Rat

**Constituents:** PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

**Research Areas:** Signal Transduction, Neuroscience

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 221780(ADRA2A Antibody) at a dilution of 1/20(Cell membrane).



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 221780(Anti-ADRA2A Antibody) at dilution 1/20.



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010